Real-world cost effectiveness comparison of symbicort turbuhaler and duoresp spiromax in UK patients with asthma or chronic obstructive pulmonary disease

J. Van Boven, H. Benhaddi, N. Roche, L. Bjermer, M. Miravitlles, J. Voorham, D. Price

Research output: Contribution to journalMeeting AbstractAcademic

Fingerprint

Dive into the research topics of 'Real-world cost effectiveness comparison of symbicort turbuhaler and duoresp spiromax in UK patients with asthma or chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Nursing and Health Professions

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases